Serum amyloid A 4 protein Antibody, Cy3 Conjugated
Referencia bs-7573R-Cy3
embalaje : 100ul
Marca : Bioss
Contact local distributor :
Teléfono : +1 850 650 7790
Serum amyloid A 4 protein Antibody, Cy3 Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-7573R-Cy3 |
| Product Name | Serum amyloid A 4 protein Antibody, Cy3 Conjugated |
| Applications | IF(IHC-P), IF(IHC-F), IF(ICC) |
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Pig, Horse, Rabbit, Guinea Pig |
| Specifications | |
| Conjugation | Cy3 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human Serum amyloid A 4 protein |
| Immunogen Range | 51-130/130 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 6291 |
| Subcellular location | Secreted |
| Synonyms | C SAA; Constitutively expressed serum amyloid A protein; CSAA; SAA 4; SAA4; SAA4 protein; Serum amyloid A 4 protein; Serum amyloid A4 constitutive; serum amyloid A-4 protein precursor. |
| Background | SAA4 is a constitutively expressed protein belonging to the SAA family. It is a major acute phase reactant and an apolipoprotein of the HDL complex. The serum amyloid A (SAA) superfamily comprises a number of differentially expressed genes with a high degree of homology in mammalian species. SAA4, an apolipoprotein constitutively expressed only in humans and mice, is associated almost entirely with lipoproteins of the high density range. Its physiological function is unknown and its serum concentration has no relationship with those of other major apolipoproteins. The presence of SAA4 mRNA and protein in macrophage derived foam cells of coronary and carotid arteries suggested a specific role of human SAA4 during inflammation including atherosclerosis. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |